|
Jan 30
|
Roche's 2024 Sales and Earnings Beat, Key Drugs Perform Well
|
|
Jan 30
|
FDA grants 510(k) clearance to Roche’s Tina-quant molarity assay
|
|
Jan 30
|
Roche Expects Sales, Earnings Growth After Better-Than-Expected Results
|
|
Jan 30
|
Roche sees high single-digit core profit growth in 2025
|
|
Jan 30
|
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth
|
|
Jan 29
|
Roche appoints chief digital technology officer
|
|
Jan 29
|
Change to the Roche Enlarged Corporate Executive Committee
|
|
Jan 28
|
Roche reports positive topline outcomes from DMD treatment trial
|
|
Jan 28
|
Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer
|
|
Jan 28
|
Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer
|
|
Jan 27
|
Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)
|
|
Jan 24
|
Stocks to watch this week: ASML, Intel, LVMH, Shell and Glencore
|
|
Jan 2
|
Innovent and Roche link on lung cancer therapy development
|
|
Oct 11
|
Roche wins first-line approval for PI3K inhibitor combo in breast cancer
|
|
Oct 11
|
Roche’s VENTANA CLDN18 assay gains CE mark
|
|
Oct 11
|
FDA clears Roche breast cancer drug; Turnstone lays off 60% of staff
|
|
Oct 11
|
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
|
|
Oct 10
|
FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
|
|
Oct 10
|
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
|
|
Oct 10
|
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.
|